Researchers tested the drug in a randomized, double-blind placebo controlled study of 412 patients.
Here’s what you should know.
1. The drug significantly reduces C. difficile infection.
2. Of the patients, there were seven confirmed infections in the placebo group and two in the ribaxamase group.
3. Patients receiving ribaxamase achieved a 71.4 percent relative risk reduction in CDI rates compared to patients receiving a placebo.
4. Adverse events reported were comparable between both groups.
More articles on gastroenterology:
Non-surgical endoscopic sleeve gastroplasty effective weight loss treatment for those with limited options
GI leader to know: Dr. Richard Panicco of Southwest Gastroenterology Associates
Study identifies biomarkers that predict which hepatitis C, cirrhosis patients improve with treatment — 2 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
